
Aravive late-stage study of AVB-500 in platinum-resistant ovarian cancer part of FDA’s innovative trial design initiative Seeking Alpha
“ovarian cancer” – Google News

Aravive late-stage study of AVB-500 in platinum-resistant ovarian cancer part of FDA’s innovative trial design initiative Seeking Alpha
“ovarian cancer” – Google News